DSIP Benefits: What the Research on Delta Sleep Inducing Peptide Actually Shows

The honest summary of the table: a striking animal story from the 1970s, a cluster of small, old human studies that disagree, and nothing at all on the subcutaneous route used today.

DSIP is a nonapeptide, nine amino acids long: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. In the early 1960s Marcel Monnier's group in Basel reported that blood from the brain of a sleeping rabbit could induce sleep-like EEG patterns in a second rabbit. The factor was isolated, sequenced and synthesised by 1977, and a Proceedings of the National Academy of Sciences paper that year named it. It was proposed as a circulating "sleep factor." The World Health Organization assigned it the name emideltide in 1993, which is what the FDA calls it. It is not a hormone, not a steroid, not related to melatonin, not a sedative and not a growth hormone secretagogue. Nearly fifty years on, no gene encoding DSIP and no DSIP receptor has been identified.

What the research describes. The defining observation, repeated in rabbits, rats and cats from 1977 onward, is more slow delta-wave and spindle power, the EEG hallmarks of deep non-REM sleep, after DSIP is given into the brain or systemically. In the 1977 paper, the synthetic peptide was the only one of nine related sequences that increased delta-wave and spindle activity when infused into rabbit brains.

The complication. It was not universal even in animals: one 1980 rat study found no change, and the original group described bell-shaped dose curves, where more did not mean more effect. A 1984 review in Neuroscience and Biobehavioral Reviews lays this out, inconsistencies included. In people, the controlled studies that measured slow-wave sleep did not find it increased.

Evidence type. Animal, not confirmed in humans.

Strength. This is the origin of the name, and the part of the story the human data did not support. A 2006 review in the Journal of Neurochemistry called the sleep-factor hypothesis "extremely poorly documented and still weak."

What the research describes. This is where DSIP's human data sits, and it is unusual for a compounded peptide: there are randomised, double-blind, placebo-controlled studies in people.

Evidence type. Human, small, mostly double-blind and placebo-controlled, all intravenous.

Strength. Mixed. The originating group reported benefit; two independent groups did not find a clinically meaningful effect. The FDA counted roughly 209 people across all of this work, all treated intravenously, none after 1992, and singled out the comparison with normal sleepers in the 1987 study as a weakness. Any source that says DSIP is established to improve sleep is overstating it; any source that says it was never tested in people is wrong the other way.

What the research describes. In the first healthy-volunteer study, subjects felt a "pressure to sleep" during the infusion but two hours later showed no sleepiness and no impaired performance. The 1981 insomnia study reported no daytime sedation, and the controlled studies that measured post-treatment nights reported no withdrawal and no rebound insomnia.

Evidence type. Human, small.

What it means. This is the main way DSIP differs from a sleeping pill: it is described as a modulator of sleep structure rather than a sedative. Approved hypnotics have large randomised trials and known dependence and next-day profiles; DSIP has small 1980s trials with mixed results and no dependence signal in the human record. Neither substitutes for the other, and a prescription sleeping medication is not stopped without the prescriber.

What the research describes. A 1985 paper in Neuroendocrinology reported that intravenous DSIP reduced corticosterone release triggered by corticotropin-releasing factor in rats, pointing to an action at the pituitary. A 2001 paper in Stress found DSIP reduced stress-induced Fos activation in the hypothalamus and septum of rats.

Evidence type. Animal.

What it means. This is where the "stress response" language comes from, and it is why DSIP is described as most relevant when poor sleep sits on top of a stress response rather than as long-standing insomnia. It is the reason SERENITY pairs DSIP with Selank, the peptide described around daytime anxiety. It has not been tested in people.

What the research describes. In rats, the opioid antagonist naloxone blocked DSIP's ability to prolong sleep. Cell work found DSIP does not bind opioid receptors directly; it was instead reported to trigger calcium-dependent release of enkephalins from neurons in several brain regions.

Evidence type. Animal and cell.

What it means. It is an indirect action, not a direct opioid effect. It is the mechanism the 1980s withdrawal studies were built on, and the reason any opioid, benzodiazepine, sedative or regular alcohol use goes on your intake.

What the research describes. A single-patient case report from 1984 described a man with narcolepsy whose sleep attacks became less frequent during weeks of intravenous dosing. A 1984 pilot study in European Neurology treated seven chronic pain patients and reported lower pain ratings in six, with no control group.

Evidence type. Human, one case and one uncontrolled pilot.

Strength. These are hypotheses, not evidence. The FDA evaluated narcolepsy as a nominated use in 2026 and the committee did not recommend DSIP.

What the research describes. A 1984 European Neurology paper from Geneva gave intravenous DSIP to 107 inpatients in alcohol or opiate withdrawal and reported symptoms resolving or improving in the large majority, with insomnia often returning afterwards. A 1998 open trial in the Journal of Clinical Psychopharmacology treated seven opioid-dependent patients and reported withdrawal scores falling after the first injection, but only two completed the schedule.

Evidence type. Human, open-label, no control group.

Strength. Weak, and both sets of authors said so. The FDA reviewed this work in 2026 and found it insufficient. This is not a use Pepti prescribes for; withdrawal is managed in addiction medicine with approved medications.

What the research describes. A 2005 paper in Seizure reported that DSIP and an analogue reduced chemically provoked seizures in rats. A 2003 study in Mechanisms of Ageing and Development gave female mice lifelong monthly courses of a DSIP-plus-glycine preparation and reported fewer chromosome aberrations, a longer maximum lifespan and fewer spontaneous tumours.

Evidence type. Animal.

What it means. The FDA's reviewers noted that glycine alone has reported anti-tumour properties, so the mouse result cannot be attributed to DSIP. Neither finding has been tested in people, and DSIP is not a seizure medication or a longevity treatment.

When the FDA's reviewers assessed emideltide for its advisory committee, they proposed that neither form be added to the 503A Bulks List, citing missing characterisation data, human effectiveness evidence they judged "inconclusive and at best preliminary," and no safety data for the subcutaneous route. On 24 July 2026 the committee voted 6 in favour, 7 against, with 1 abstention, and did not recommend it; it was the only one of the seven peptides considered that week not to receive a favourable vote. The vote is advisory and the FDA's final determination is pending. DSIP was removed from Category 2 on 15 April 2026 and remains legal to prescribe and dispense.

In the small insomnia studies, DSIP was reported as well tolerated with no significant adverse events, and the FDA's adverse event database search for emideltide, through March 2024, returned zero reports. There is no subcutaneous safety data and no established interaction list. Laboratory work reports DSIP being broken down by an enzyme that some blood-pressure medicines inhibit, so every medication you take belongs on your intake. DSIP is not used in pregnancy or breastfeeding.

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. The dosing detail is in DSIP dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial.

When something else makes more sense

• You have not tried CBT-I. Cognitive behavioural therapy for insomnia is the first-line recommendation of every major sleep guideline and has large human trials behind it.
• Anxiety is what keeps you awake. Selank is described around anxiolytic signalling during the day.
• Your rhythm is off rather than your depth. Epithalon is described around the pineal gland and circadian timing; see what is Epithalon.
• Your interest is really the growth hormone pulse. Growth hormone release is concentrated in slow-wave sleep, but DSIP is not aimed at that axis; CJC-1295 / Ipamorelin and sermorelin are.
• A breathing problem at night. DSIP is not a treatment for sleep apnoea.

The wider category is in peptides for sleep.

DSIP cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes DSIP in every state except Oklahoma, plus DC The step-by-step page is how to get DSIP prescribed online. The blend is covered in what is the SERENITY blend.